Alnylam's growth hinges on slowing heart drug Amvuttra; $100B valuation at risk

Alnylam's flagship heart drug Amvuttra is experiencing slowing sales, threatening the company's growth trajectory and its ambition to reach a $100 billion market valuation. The company's heavy dependence on this single product amplifies the risk, as no clear catalyst has emerged to offset the deceleration. This development signals potential downside for Alnylam's stock and raises questions about its pipeline diversification.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works